Orexo completes 1,080 patient REZOLV study and reports on improved treatment of opioid dependent patients
Uppsala, Sweden, September 2, 2016 – Orexo AB (publ.) announces that the REZOLV retrospective study (Retrospective Evaluation of Zubsolv® Outcomes – A Longitudinal View) has been completed as planned in August. With 1,080 patients, the study is the largest retrospective study completed in the US aimed at optimizing the treatment of opioid dependence. The opioid epidemic in the US continues to increase, and with recent legislative changes in the US that expand access to treatment, the current annual growth of nearly 9 percent of patients treated is expected to accelerate significantly.